Evidence-based treatment of voice and speech disorders in Parkinson disease

Purpose of review Voice and speech impairments are present in nearly 90% of people with Parkinson disease and negatively impact communication and quality of life. This review addresses the efficacy of Lee Silverman Voice Treatment (LSVT) LOUD to improve vocal loudness (as measured by vocal sound pressure level vocSPL) and functional communication in people with Parkinson disease. The underlying physiologic mechanisms of Parkinson disease associated with voice and speech changes and the strength of the current treatment evidence are discussed with recommendations for best clinical practice. Recent findings Two randomized control trials demonstrated that participants who received LSVT LOUD were significantly better on the primary outcome variable of improved vocSPL posttreatment than alternative and no treatment groups. Treatment effects were maintained for up to 2 years. In addition, improvements have been demonstrated in associated outcome variables, including speech rate, monotone, voice quality, speech intelligibility, vocal fold adduction, swallowing, facial expression and neural activation. Advances in technology-supported treatment delivery are enhancing treatment accessibility. Summary Data support the efficacy of LSVT LOUD to increase vocal loudness and functional communication in people with Parkinson disease. Timely intervention is essential for maximizing quality of life for people with Parkinson disease.

[1]  E. Barbosa,et al.  Telerehabilitation in Parkinson's disease: Influence of cognitive status , 2016, Dementia & neuropsychologia.

[2]  Shimon Sapir,et al.  Multiple factors are involved in the dysarthria associated with Parkinson's disease: a review with implications for clinical practice and research. , 2014, Journal of speech, language, and hearing research : JSLHR.

[3]  Lorraine O. Ramig,et al.  Effects of the Lee Silverman Voice Treatment (LSVT® LOUD) on Hypomimia in Parkinson's Disease , 2014, Journal of the International Neuropsychological Society.

[4]  Carola Seifried,et al.  Pathomechanisms and compensatory efforts related to Parkinsonian speech , 2013, NeuroImage: Clinical.

[5]  Jennifer L. Spielman,et al.  Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease. , 2012, American journal of speech-language pathology.

[6]  G. Ebersbach,et al.  LSVT LOUD and LSVT BIG: Behavioral Treatment Programs for Speech and Body Movement in Parkinson Disease , 2012, Parkinson's disease.

[7]  D. Suiter,et al.  Sentence intelligibility before and after voice treatment in speakers with idiopathic Parkinson's disease. , 2012, Journal of voice : official journal of the Voice Foundation.

[8]  Jennifer L. Spielman,et al.  Intensive voice treatment (LSVT®LOUD) for Parkinson's disease following deep brain stimulation of the subthalamic nucleus. , 2011, Journal of communication disorders.

[9]  L. Ramig,et al.  Telepractice Supported Delivery of LSVT®LOUD , 2011 .

[10]  T. Whitehill,et al.  Effect of LSVT on Lexical Tone in Speakers with Parkinson's Disease , 2011, Parkinson's disease.

[11]  Shimon Sapir,et al.  Intensive voice treatment in Parkinson’s disease: Lee Silverman Voice Treatment , 2011, Expert review of neurotherapeutics.

[12]  Jessica E. Huber,et al.  Effect of Parkinson's disease on the production of structured and unstructured speaking tasks: respiratory physiologic and linguistic considerations. , 2011, Journal of speech, language, and hearing research : JSLHR.

[13]  Stephen Wilson,et al.  Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial. , 2011, International journal of language & communication disorders.

[14]  M I Hariz,et al.  Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease , 2010, Neurology.

[15]  Jennifer L. Spielman,et al.  Formant centralization ratio: a proposal for a new acoustic measure of dysarthric speech. , 2010, Journal of speech, language, and hearing research : JSLHR.

[16]  K. Leenders,et al.  Parkinson's disease: The syndrome, the pathogenesis and pathophysiology , 2009, Cortex.

[17]  Peter T Fox,et al.  Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance–correlation analysis , 2009, Human brain mapping.

[18]  T. Pring,et al.  Delivering the Lee Silverman Voice Treatment (LSVT) by web camera: a feasibility study. , 2009, International journal of language & communication disorders.

[19]  R. Schmidt,et al.  Principles of motor learning in treatment of motor speech disorders. , 2008, American journal of speech-language pathology.

[20]  J. Ahlskog.  Beating a dead horse , 2007, Neurology.

[21]  Jennifer L. Spielman,et al.  Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. , 2007, Journal of speech, language, and hearing research : JSLHR.

[22]  Jennifer L. Spielman,et al.  Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease. , 2007, American journal of speech-language pathology.

[23]  Stephen Wilson,et al.  Treating the speech disorder in Parkinson's disease online , 2006 .

[24]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[25]  Nick Miller,et al.  Life with communication changes in Parkinson's disease. , 2006, Age and ageing.

[26]  A. Benabid,et al.  Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech , 2005, Movement disorders : official journal of the Movement Disorder Society.

[27]  Patrick Santens,et al.  The effects of levodopa on word intelligibility in Parkinson's disease. , 2005, Journal of communication disorders.

[28]  Canan Ozsancak,et al.  Treatments for dysarthria in Parkinson's disease , 2004, The Lancet Neurology.

[29]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[30]  K. Tjaden,et al.  Rate and loudness manipulations in dysarthria: acoustic and perceptual findings. , 2004, Journal of speech, language, and hearing research : JSLHR.

[31]  Scott T. Grafton,et al.  The basal ganglia network mediates the planning of movement amplitude , 2004, The European journal of neuroscience.

[32]  Jessica E. Huber,et al.  Respiratory Function and Variability in Individuals with Parkinson Disease: Pre- and Post-Lee Silverman Voice Treatment , 2003 .

[33]  Scott T. Grafton,et al.  Basal ganglia network mediates the control of movement amplitude , 2003, Experimental Brain Research.

[34]  Jennifer L. Spielman,et al.  The Effects of Intensive Voice Treatment on Facial Expressiveness in Parkinson Disease: Preliminary Data , 2003, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[35]  P T Fox,et al.  Hypophonia in Parkinson’s disease , 2003, Neurology.

[36]  M. Horstink,et al.  Improvement of voicing in patients with Parkinson’s disease by speech therapy , 2003, Neurology.

[37]  Lorraine O. Ramig,et al.  Speech Loudness and Quality 12 Months after Intensive Voice Treatment (LSVT®) for Parkinson’s Disease: A Comparison with an Alternative Speech Treatment , 2002, Folia Phoniatrica et Logopaedica.

[38]  L. Ramig,et al.  Current Perspectives on the Lee Silverman Voice Treatment (LSVT) for Individuals With Idiopathic Parkinson Disease , 2002 .

[39]  C. Coelho,et al.  Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states. , 2002, Journal of communication disorders.

[40]  Jeri Logemann,et al.  Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study , 2002, INTERSPEECH.

[41]  T. Zeffiro,et al.  Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease. , 2001, Journal of speech, language, and hearing research : JSLHR.

[42]  M. Hallett,et al.  Pathophysiology of bradykinesia in Parkinson's disease. , 2001, Brain : a journal of neurology.

[43]  S. Countryman,et al.  Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up , 2001 .

[44]  R Iansek,et al.  Motor instability in parkinsonian speech intensity. , 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.

[45]  S. Sapir,et al.  Voice quality changes following phonatory-respiratory effort treatment (LSVT) versus respiratory effort treatment for individuals with Parkinson disease. , 2001, Journal of voice : official journal of the Voice Foundation.

[46]  S. Countryman,et al.  Changes in vocal loudness following intensive voice treatment (LSVT®) in individuals with Parkinson's disease: A comparison with untreated patients and normal age‐matched controls , 2001, Movement disorders : official journal of the Movement Disorder Society.

[47]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[48]  A. Graybiel,et al.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.

[49]  E S Luschei,et al.  Thyroarytenoid muscle activity associated with hypophonia in Parkinson disease and aging , 1998, Neurology.

[50]  S. Countryman,et al.  Supraglottal Hyperadduction in an Individual With Parkinson Disease , 1997 .

[51]  S. Countryman,et al.  Intensive speech treatment for patients with Parkinson's disease , 1996, Neurology.

[52]  L. Ramig,et al.  Aerodynamic mechanisms underlying treatment-related changes in vocal intensity in patients with Parkinson disease. , 1996, Journal of speech and hearing research.

[53]  L. Ramig,et al.  Intensive voice treatment in Parkinson disease: laryngostroboscopic findings. , 1995, Journal of voice : official journal of the Voice Foundation.

[54]  S. Countryman,et al.  Comparison of two forms of intensive speech treatment for Parkinson disease. , 1995, Journal of speech and hearing research.

[55]  L. Ramig,et al.  Phonatory and articulatory changes associated with increased vocal intensity in Parkinson disease: a case study. , 1995, Journal of speech and hearing research.

[56]  J. Duffy.  Motor Speech Disorders: Substrates, Differential Diagnosis, and Management , 1995 .

[57]  N. Solomon,et al.  Speech breathing in Parkinson's disease. , 1993, Journal of speech and hearing research.

[58]  G. Weismer,et al.  Kinematic, acoustic, and perceptual analyses of connected speech produced by parkinsonian and normal geriatric adults. , 1989, The Journal of the Acoustical Society of America.

[59]  C. Markham,et al.  Deficits in orofacial sensorimotor function in Parkinson's disease , 1986, Annals of neurology.

[60]  M. Cosio,et al.  Involvement of upper-airway muscles in extrapyramidal disorders. A cause of airflow limitation. , 1984, The New England journal of medicine.

[61]  Katunina Ea,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[62]  Anthony H V Schapira,et al.  Neurobiology and treatment of Parkinson's disease. , 2009, Trends in pharmacological sciences.

[63]  B. Murdoch,et al.  Changes in Maximum Capacity Tongue Function following the Lee Silverman Voice Treatment Program , 2000 .

[64]  R. Iansek,et al.  Speech impairment in a large sample of patients with Parkinson's disease. , 1998, Behavioural neurology.

[65]  L. Ramig,et al.  The Parkinson larynx: tremor and videostroboscopic findings. , 1996, Journal of voice : official journal of the Voice Foundation.

[66]  L. Raming,et al.  Voice treatment for patients with Parkinson desease: Development of an approach and preliminary efficacy data , 1994 .